Clinical Report: Plasma pTau217 Cutoffs for Clinical Use
Overview
Revise to specify how the double-cutoff strategy in obesity increases the need for confirmatory imaging.
Background
Plasma p-tau217 is a promising biomarker for Alzheimer's disease, but its diagnostic utility can be affected by comorbid conditions such as kidney dysfunction and anemia. Understanding how these factors influence p-tau217 levels is critical for accurate diagnosis and management of Alzheimer's disease, particularly in diverse patient populations.
Data Highlights
Condition
Standard Cutoff Accuracy
Subgroup-Specific Cutoff Accuracy
Chronic Kidney Disease
0.65
0.83
Anemia
0.80
0.86
Key Findings
Kidney dysfunction and anemia elevate baseline plasma p-tau217 levels.
Subgroup-specific cutoffs improved diagnostic accuracy significantly in chronic kidney disease and anemia.
The double-cutoff strategy reduced false classifications but resulted in 39% intermediate results requiring further imaging.
Optimal cutoffs provided a favorable balance of diagnostic accuracy and cost efficiency in chronic kidney disease and anemia.
Plasma p-tau217 concentrations were inversely associated with estimated glomerular filtration rate, body mass index, and hemoglobin.
Clinical Implications
Highlight the importance of diverse patient populations in implementing findings.
Conclusion
The study underscores the importance of biologically informed approaches in the use of plasma p-tau217 for Alzheimer's disease diagnosis, particularly in patients with comorbid conditions. Further validation in diverse populations is necessary to generalize these findings.
